GB2474209B - Sertraline composition - Google Patents

Sertraline composition

Info

Publication number
GB2474209B
GB2474209B GB1102349.6A GB201102349A GB2474209B GB 2474209 B GB2474209 B GB 2474209B GB 201102349 A GB201102349 A GB 201102349A GB 2474209 B GB2474209 B GB 2474209B
Authority
GB
United Kingdom
Prior art keywords
sertraline composition
sertraline
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
GB1102349.6A
Other versions
GB2474209A (en
GB201102349D0 (en
Inventor
Ingrid Soderberg
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Rosemont Pharmaceuticals Ltd
Original Assignee
Rosemont Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rosemont Pharmaceuticals Ltd filed Critical Rosemont Pharmaceuticals Ltd
Publication of GB201102349D0 publication Critical patent/GB201102349D0/en
Publication of GB2474209A publication Critical patent/GB2474209A/en
Application granted granted Critical
Publication of GB2474209B publication Critical patent/GB2474209B/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
GB1102349.6A 2008-08-07 2009-07-08 Sertraline composition Active GB2474209B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0814466.9A GB0814466D0 (en) 2008-08-07 2008-08-07 Sertraline composition
PCT/GB2009/001700 WO2010015797A1 (en) 2008-08-07 2009-07-08 Sertraline composition

Publications (3)

Publication Number Publication Date
GB201102349D0 GB201102349D0 (en) 2011-03-30
GB2474209A GB2474209A (en) 2011-04-06
GB2474209B true GB2474209B (en) 2012-02-22

Family

ID=39767674

Family Applications (2)

Application Number Title Priority Date Filing Date
GBGB0814466.9A Ceased GB0814466D0 (en) 2008-08-07 2008-08-07 Sertraline composition
GB1102349.6A Active GB2474209B (en) 2008-08-07 2009-07-08 Sertraline composition

Family Applications Before (1)

Application Number Title Priority Date Filing Date
GBGB0814466.9A Ceased GB0814466D0 (en) 2008-08-07 2008-08-07 Sertraline composition

Country Status (2)

Country Link
GB (2) GB0814466D0 (en)
WO (1) WO2010015797A1 (en)

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0768083A2 (en) * 1995-07-17 1997-04-16 Pfizer Inc. The use of sertraline to treat post myocardial infarction patients
WO1999062522A1 (en) * 1998-05-29 1999-12-09 Eli Lilly And Company Combination therapy for treatment of bipolar disorders
US20050070577A1 (en) * 2003-07-03 2005-03-31 Pfizer Inc. Compositions containing a serotonin selective reuptake inhibitor and a 5-HT2A receptor antagonist
WO2005117911A2 (en) * 2004-05-06 2005-12-15 Cydex, Inc. Taste-masked formulations containing sertraline and sulfoalkyl ether cyclodextrin
US20070213562A1 (en) * 2006-01-23 2007-09-13 Ami Zoran Recycling process for preparing sertraline
US20070215511A1 (en) * 2006-03-16 2007-09-20 Tris Pharma, Inc. Modified release formulations containing drug-ion exchange resin complexes
WO2008020150A1 (en) * 2006-08-18 2008-02-21 Syngenta Limited Use of hppd inhibitors in the treatment of depression and/or withdrawal symptoms associated with addictive drugs

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0768083A2 (en) * 1995-07-17 1997-04-16 Pfizer Inc. The use of sertraline to treat post myocardial infarction patients
WO1999062522A1 (en) * 1998-05-29 1999-12-09 Eli Lilly And Company Combination therapy for treatment of bipolar disorders
US20050070577A1 (en) * 2003-07-03 2005-03-31 Pfizer Inc. Compositions containing a serotonin selective reuptake inhibitor and a 5-HT2A receptor antagonist
WO2005117911A2 (en) * 2004-05-06 2005-12-15 Cydex, Inc. Taste-masked formulations containing sertraline and sulfoalkyl ether cyclodextrin
US20070213562A1 (en) * 2006-01-23 2007-09-13 Ami Zoran Recycling process for preparing sertraline
US20070215511A1 (en) * 2006-03-16 2007-09-20 Tris Pharma, Inc. Modified release formulations containing drug-ion exchange resin complexes
WO2008020150A1 (en) * 2006-08-18 2008-02-21 Syngenta Limited Use of hppd inhibitors in the treatment of depression and/or withdrawal symptoms associated with addictive drugs

Also Published As

Publication number Publication date
GB2474209A (en) 2011-04-06
GB0814466D0 (en) 2008-09-10
WO2010015797A1 (en) 2010-02-11
GB201102349D0 (en) 2011-03-30

Similar Documents

Publication Publication Date Title
GB0815022D0 (en) Composition
GB0819633D0 (en) Composition
GB0822246D0 (en) Composition
GB0801119D0 (en) Composition
GB0818473D0 (en) Composition
GB0810554D0 (en) Herbicde composition
GB0809808D0 (en) Composition
GB0818472D0 (en) Composition
GB0811743D0 (en) Composition
GB0801401D0 (en) Composition
EP2357204A4 (en) Composition
GB0810359D0 (en) Composition
GB0817656D0 (en) Composition
GB0812740D0 (en) Composition
GB0806948D0 (en) Composition
GB0818269D0 (en) Composition
GB0813589D0 (en) Composition
GB0809983D0 (en) Composition
GB0903681D0 (en) Composition
GB0823344D0 (en) Composition
GB0821754D0 (en) Composition
GB0818231D0 (en) Composition
GB0820259D0 (en) Composition
GB0818336D0 (en) Composition
GB0814101D0 (en) Composition